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Abstract
Background: 3MC1 syndrome is a rare autosomal recessive disorder characterized by intellectual disability,
short stature and distinct craniofacial, umbilical, and sacral anomalies. Five mutations in MASP1, encoding
lectin complement pathway enzymes MASP-1 and MASP-3, have thus far been reported to cause 3MC1
syndrome. Only one previously reported mutation affects both MASP-1 and MASP-3, while the other
mutations affect only MASP-3.
Methods: We evaluated six unrelated individuals with 3MC1 syndrome and performed Sanger sequencing for all
coding exons of MASP1. We also measured complement lectin and alternative pathway activities in an affected
individual’s serum.
Results: We found two novel splice site mutations, c.1012-2A > G in one and c.891 + 1G > T in two probands, and
three novel missense mutations, c.1451G > A (p.G484E), c.1657G > A (p.D553N), and c.1987G > T (p.D663Y). Missense
mutations affect only MASP-3, while splice site mutations affect both MASP-1 and MASP-3. In a proband who is
homozygous for c.891 + 1G > T, we detected a total lack of lectin complement pathway activity and a 2.5-fold
lower alternative pathway activity. The phenotype observed in patients whose both MASP-1 and MASP-3 are
affected and in those whose only MASP-3 is affected does not appear to be different. We observed structural
brain abnormalities, neonatal tooth, a vascular anomaly and a solid lesion in liver as novel phenotypic features
of 3MC1 syndrome.
Conclusion: Novel mutations and additional phenotypic features expand the genotypic and phenotypic spectrum of
3MC1 syndrome. Although patients with MASP-1 dysfunction in addition to disrupted MASP-3 have an altered
complement system, their disease phenotype is not different from those having only MASP-3 dysfunction.
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Background
3MC syndrome (MIM 257920;265050;248340) is char-
acterized by distinctive facial features including hyper-
telorism, blepharophimosis, blepharoptosis, highly
arched eyebrows, and cleft lip/palate, postnatal growth
retardation, variable degree of developmental delay or
intellectual disability, and hearing loss. Craniosynostosis,
radioulnar synostosis, genital and vesicorenal anomalies,
caudal appendage, and umbilical hernia/ omphalocele or
periumbilical depression are also often seen in this syn-
drome. 3MC syndrome has been named by lumping
Michels, Malpuech, Mingarelli and Carnevale syndromes,
which were originally reported to be separate entities with
overlapping features [1, 2].
Mutations in two genes, MASP1 (MIM 600521) and
COLEC11 (MIM 612502), which both encode proteins
playing important roles in the lectin complement path-
way, were found to be responsible for 3MC syndrome
[3, 4]. While there is no recognized phenotypic differ-
ence, OMIM classifies individuals having mutations in
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MASP1 and COLEC11 under 3MC1 (MIM 257920) and
3MC2 (MIM 265050) syndromes, respectively. The
MASP1 gene is located on chromosome 3q27-28 and
gives rise to three alternative splice products playing
roles in the lectin pathway of the innate immune system:
MASP-1, MASP-3, and MAp44 [5–7]. The gene is com-
posed of 18 exons; the three alternative splice products
share the same first eight exons encoding the first four
domains of the proteins. The serine protease (SP) do-
mains of MASP-1 and MASP-3 are encoded by separate
exons, whereas no SP domain is present in MAp44
(Fig. 1). The SP domain of MASP-1 is encoded by six
separate exons (13–18), while MASP-3 is encoded by a
single exon (12) [8–10]. In this study, we report on six
previously unreported children with 3MC1 syndrome
and the results of their molecular investigations.
Methods
Six unrelated probands clinically diagnosed with 3MC
syndrome and their parents were included in this
study. Written informed consent was obtained from all
participants. The study was approved by the Institutional
Review Board at the University of Miami.
Molecular studies
Genomic DNA was extracted from peripheral leukocytes
according to standard protocols. Sanger sequencing for
all coding exons of the MASP1 gene was performed on
all patients and mutated exons were analyzed for cose-
gregation in their unaffected parents (primer sequences
are available on request). A touchdown PCR protocol
was used to amplify target DNA region. The resulting
amplicons were cleaned up using Sephadex G-25 beads
(GE Healthcare). An ABI PRISM 3730 DNA analyzer
(Applied Biosystems) and Big Dye Terminator Cycle
Sequencing V3.1 Ready Reaction Kit (Life Technologies)
were used to elucidate the DNA sequence. Variants were
named according to NM_139125.3.
To evaluate the implication of splice site mutations, we
used The Berkeley Drosophila Genome Project (PDGP)
Fig. 1 a Overview of MASP1 mutations. Exons and introns are indicated by circles with numbers and thin lines, respectively. The localization of
mutations identified in this study is shown with blue arrows; those reported by Sirmaci et al.[3] and Rooryck et al. [4] are shown with
red arrows; b Overview of the resulting protein structures of the three mRNA sequences produced from MASP1. In protein domains of these different
transcripts, the blue arrows and red arrows show the mutations presented in this study and reported previously, respectively [3, 4]
Atik et al. Orphanet Journal of Rare Diseases  (2015) 10:128 Page 2 of 10
(http://www.fruitfly.org/) as a splice site prediction pro-
gram. Missense variants were analyzed for having a
pathogenic prediction score at least in two of the fol-
lowing tools: PolyPhen2, SIFT, and MutationTaster.
PhyloP and GERP scores were used to evaluate the
levels of conservation of the regions in which the muta-
tions were located [11–16].
Functional studies
The levels of MASP-1, MASP-3 and MAp44 were mea-
sured by sandwich type immunoassays by the use of
europium labelled detection reagent and measurement
by time-resolved fluorescence as previously described
in detail [17].
For measurement of the activity of the alternative
pathway of complement, we followed a previously pub-
lished procedure for the estimation of the ability of a
sample to mediate lysis of rabbit erythrocytes, in a buffer
inhibiting the classical and the lectin pathway of comple-
ment as described [17]. Serum samples were diluted in
gelatin-veronal buffer with magnesium and EGTA (a
negative control containing EDTA buffer was also in-
cluded). Twenty microliters of each dilution was mixed
with 10 μl 6 % (v/v) rabbit erythrocytes in the same buf-
fer and the mixture incubated for 2 h at 37 °C after
which the lysis reactions were stopped by the addition of
EDTA, and the mixture centrifuged followed by reading
the absorbance at 405 nm of the supernatant.
The estimation of functional activity of the lectin path-
way followed a previously published procedure that mea-
sures the ability of a serum to deposit C4 fragments
onto a mannan surface [17]. Since the serum from pa-
tient 3 contains a low mannan binding lectin (MBL)
level (i.e. is MBL deficient) it was reconstituted to
physiological MBL level (2 μg MBL/ml) with recombin-
ant MBL. The normal serum we used for comparison
was also MBL deficient and was similarly added MBL to
2 μg/ml. Sera were diluted in calcium containing buffer
and added to mannan-coated microtiter wells. After in-
cubation overnight at 4 °C the wells were washed and
now purified human C4 was added. After incubation at
37 °C for 1 h, during which period C4b is deposited on
the surface, the wells were washed, and biotinylated
anti-C4 antibody was added. After incubation and wash
europium-labeled streptavidin was added. After incuba-
tion and wash an enhancement solution was added,
followed by reading of time-resolved fluorescence.
Results
Clinical features
The ages of probands ranged from 4 months to 22 years.
There were three males and three females. All six pa-
tients were born at term. Their weights, heights and
head circumferences were in normal limits at birth but
three of them showed postnatal growth retardation. Pedi-
grees, photographs and clinical features of all patients are
shown in Table 1, Fig. 2 and Additional file 1: Figure S1.
Patients 1 and 6 showed a more severe clinical presen-
tation and poor prognosis.
In patient 1, bilateral cleft lip and palate, left clubfoot,
neonatal tooth, omphalocele and a sacral dimple with a
hairy patch were noted at birth. Early gross motor devel-
opmental milestones were moderately delayed, however
at the age of 2 years, the patient developed meningitis
and subsequently his developmental milestone acquisi-
tion slowed or plateaued in all spheres. At his current
age of 4 years 6 months, he is able to walk with support
but unable to feed himself. He makes no eye contact and
has not developed alternative means of communication,
in part due to profound hearing loss. He remains G-tube
fed, and his weight and height are both 5–6 SD below
the mean. On ophthalmologic examination, he was
noted to have left sided Peter’s anomaly, in addition to
hypermetropia. Brain MRI indicated absent olfactory
bulbs, small pituitary gland, small thin corpus callosum
and severe narrowing of the foramen magnum. A spinal
MRI also revealed adequate alignment with conus
medullaris at L3, and a 9 mm intrathecal cyst in the dis-
tal sac. A secundum atrial septal defect (ASD), patent
ductus arteriosus (PDA) and pulmonary hypertension
were detected on echocardiogram.
Patient 6 was noticed to have bilateral cleft lip and pal-
ate, and clitoromegaly at birth. Echocardiography re-
vealed a secundum ASD with a wide PDA. A diagnostic
work up including a head ultrasound, serum electrolytes,
detailed biochemical screening such as liver enzymes,
and renal function tests, were all within normal limits.
Abdominal ultrasound showed a heterogeneous hypoe-
choic solid lesion of 38 × 24 mm, containing serpiginous
tubular structures, in the anterior segment of the right
lobe of the liver; the left renal agenesis was also ob-
served. On examination at 6 months of age, she had a
weight of 3200 g (<3th centile), height of 58 cm (<3th
centile), and head circumference of 39 cm (<3th centile).
Anterior fontanelle was 3 × 4 cm, and posterior fonta-
nelle was still palpable as 1 × 1 cm. In addition to typical
facial features of 3MC syndrome, clitoromegaly of 1.5 cm,
anterior ectopic anus, prominent coccyx with a sacral pit,
and a presacral capillary malformation of 2 × 3 cm were
observed. She was hypotonic with normal deep tendon
reflexes. Head control was not achieved. Although cell
culture from peripheral blood lymphocytes was unsuc-
cessful, interphase FISH study with centromeric probes
showed two signals for X chromosome and none for Y.
17-hydroxyprogesteron, androstenedione, cortisol levels,
and plasma renin activity were normal. The patient under-
went a successful PDA ligation operation, but unfortu-
nately died 2 months later due to pneumonia.
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Table 1 A summary of MASP1 mutations and phenotypic features of affected individuals
Patients described in the present report Previously reported patients
Patient no (P) P2 P3 P4 P1 P5 P6 II-1013 MC6_12,4 MC6_22,4 MC7_14,22 MC7_2
4,22































Mutation (protein) splice splice splice p.G484E p.D553N p.D663Y p.W290X p.G666E p.G666E p.G666E p.G666E p.G687R p.G687R p.H497Y p.C630R p.C630R
Localization Intron 7 Intron 6 Intron 6 Exon 12 Exon 12 Exon 12 Exon 6 Exon 12 Exon 12 Exon 12 Exon 12 Exon 12 Exon 12 Exon 12 Exon 12 Exon12
Origin Turkey Turkey Turkey Pakistan Turkey Syria Turkey Brazil Brazil Brazil Brazil Turkey Turkey Greece Italy Italy
Consanguinity + + + + + + + - - + + + + + - -
Age 15 years 6.5 years 4 months 4.5 years 22 years 6 months 9 years 20 years 14 years 23 years 17 years 15 years 10 years NA NA NA
Gender F F M M F M F F M M M F F M M M





- - NA + - NA + - - - - + + - - -
Craniosynostosis/
Skull asymmetry
NA - + NA + - NA - - - - NA NA + - -
Arched eyebrows + + + + + + + + + + + + + + + +
Hypertelorism + + + + + + - + + + + + + + + +




+ + + + + + + + + + + + + + + +
Anterior chamber
anomalies
- +#3 - +#2 - - - + - - - - - - - -
Hearing loss - - + + + NA - + + + + + + - + +
Cleft lip/palate - - + + + + - - - + + + + + + +
Periumbilical
depression
+ + + NA + - + + - + + + + - - -
Omphalocele/
Umblical hernia




- - - - - - - + - + + + - - - -
Genital anomalies - - +#5 - - +#9 - - + + + - - - + +
Vesicorenal anomalies - +#4 +#6 - - +#10 + - - - + + - + - -
Caudal appendage
and/or spina bifida















Table 1 A summary of MASP1 mutations and phenotypic features of affected individuals (Continued)
Cardiac - PDA PDA ASD, PDA - ASD, PDA PDA - - - - - - - - -
Structural anomaly
in Cranial/Spinal MRI
















NA: not available; ASD: atrial septal defect; PDA: patent ductus arteriosus; SPO: Spina bifida occulta; mutations affecting all protein products of MASP1 are grayed
#1: Absent olfactory bulbs, small pituitary gland, small thin corpus callosum and severe narrowing of the foramen magnum in cranial MRI, and adequate alignment with conus medullaris at L3, and a 9 mm intrathecal
cyst in the distal sac in spinal MRI; #2: Left sided Peter’s anomaly; #3: Bilateral leukoma; #4: Cross renal ectopia; #5: Ambiquous genitalia; #6: Horseshoe kidney; #7: Spinal MRI at 2 years of age revealed a spina bifida
between L3 and the sacrum, lumbosacral dural sac ectasia, an intradural dermoid tethering of the cord between L2 and S4, with a thickened filum terminale at L2. She underwent an operation for excision of the cystic
tumor, tethered cord, and bone repair; #8: Growth hormone treatment was administered for the patient until 17 years of age; #9: Cliteromegaly of 1.5 cm, anterior ectopic anus, prominent coccyx with a sacral pit, and
a presacral capillary malformation of 2 × 3 cm were observed; #10: Left renal agenesis; #11: Abdominal ultrasound showed a heterogeneous hypoechoic solid lesion of 38 × 24 mm, containing serpiginous tubular















Patient 4 was followed up until age 4.5 months and
did not present with significant clinical problems other
than features described in Table 1.
In three older patients (patients 2, 3, and 5) long term
follow ups were available. Patient 2 showed normal de-
velopmental milestones from birth to 15 years old and
did not experience any significant health problem.
Patient 3 presented with recurrent bronchiolitis epi-
sodes and her weights, heights and head circumferences
were in lower limits of normal at the age of 6. She had
normal cognitive functions.
Patient 5 underwent an operation for excision of
the cystic tumor, tethered cord, and bone repair be-
cause of her lumbosacral anomalies at the age of 2.
Her neuromotor development was on target except
for a mild speech delay. Audiometric evaluation re-
vealed moderate conductive hearing loss on the right,
due to chronic otitis media. At 9 years and 2 months
of age, her height was 122.5 cm (3rd centile), weight
was 21.7 kg (3–10th centile), and head circumference
was 52 cm (25–50th centile). A WISC-R IQ score was
98. At age 12, she was evaluated for short stature,
and was found to have growth hormone deficiency.
Growth hormone treatment was administered until
age 17. At 22 years of age, her height was 153 cm
(3–10th centile), weight was 40 kg (<3th centile), and
head circumference was 54.5 cm (3–10th centile). She
was working as a clerk in a state institution, and did
not report additional health problems.
Molecular findings
We detected five novel mutations in the MASP1 gene
(Fig. 1 and Additional file 1: Figure S2). One mutation,
affecting the splice donor site in intron 6 (c.891 + 1G > T),
was found in two probands (Patient 3 and 4). Another
splice site mutation was found in the acceptor site of in-
tron 8 (c.1012-2A >G)(Patient 2). As expected from their
locations at consensus splice sites, both c.891 + 1G > T
and c.1012-2A >G were found to be in highly conserved
regions: PhyloP scores are 4.88 for both and GERP scores
are 5.73 and 5.7, respectively. The c. 891 + 1G > T is pre-
dicted to lead to the skipping of exon 6 affecting both
MASP-1 and MASP-3 proteins. The second splice site
mutation, c.1012-2A >G, is predicted to lead to replace
the acceptor site of exon 8 with a new site located 239 bp
upstream of that point.
The other three mutations were missense (p.G484E in
Patient 1, p.D553N in Patient 5, and p.D663Y in Patient 6),
located in exon 12. None of these was present as homozy-
gous variation in the EVS (http://evs.gs.washington.edu/
EVS/) and ExAC databases (http://exac.broadinstitute.org/).
All missense mutations were predicted to be disease caus-
ing when tested using in silico prediction tools (Polyphen,
MutationTaster, and SIFT) and were located in very
conserved regions. According to an in silico protein
structure analysis (HOPE) [18], of these missense mu-
tations, p.G484E and p.D663Y were located in part of
4 different interpro domains (Peptidase S1; Peptidase
S1A, chymotrypsin-type; trypsin-like cysteine/serine
peptidase; Peptidase S1A, complement C1r/C1S/man-
nan-binding) which are important for the main activ-
ity of the protein. The mutations in these regions can
disturb the core structure of the protein and thereby
affect the catalytic activity. The other missense muta-
tion identified in this study, p.D553N, is located in
the active site and a mutation at this site is, always, ex-
pected to disturb the function of the protein [19]. All vari-
ants co-segregated with the phenotype as an autosomal
recessive disease in available family members (parental
samples were not available for patient 1).
Functional characterization of complement pathways
In the present report we tested the serum levels of
MASP-1, MASP-3 and MAp44 of patient 3, who is
homozygous for c.891 + 1G > T. For all three proteins we
did not detect a signal. We further found that the pa-
tient was MBL deficient, i.e. MBL level was below
100 ng/ml (this occurs in approximately 10 % of the
general population).
Fig. 2 Photographs showing distinctive phenotypic features in Patients 2-6
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In the literature there have been reports on the in-
volvement of MASP-1 and MASP-3 on the alternative
pathway activity of serum [20, 21]. We have previously
seen that a patient devoid of MASP-1 and MASP-3
still contained the ability to lyse rabbit erythrocytes,
which is traditionally used for testing the activity of
the alternative pathway [17]. We found that patient 3
from the present report, who has no MASP-1 and
MASP-3 still had the ability to initiate the alternative
pathway (Fig. 3a). The activity was 2.5-fold lower than
the sample from a normal healthy individual tested at
the same time and the negative control including
EDTA in the buffer gave only background levels. The
function of MASP-1 is described as activating MASP-
2, which then cleaves C4 and thus generating the C4b
form, which may covalently bind to nearby surfaces.
When we tested the ability of patient 3 serum to de-
posit C4b onto a mannan surface, we found very low
C4b deposition as compared to a normal human
serum (Fig. 3b). This assay is dependent on the MBL
concentration of the serum tested, but in this case we
were lucky that patient 3 is MBL deficient and we
could thus control the amount of MBL by adding a
known amount of MBL to the serum. We then picked
a MBL deficient serum from a blood donor cohort and
added the same amount of MBL for comparison. We
furthermore examined whether the MBL pathway
would be affected by reconstitution of the patient
serum with recombinant MASP-1 and found this to be
the case, whereas no increase of MBL pathway activity
was found in the normal serum when rMASP-1 was
added (not shown).
Discussion
The MBL-associated serine proteases (MASPs), MASP-1,
MASP-2 and MASP-3, are proteins playing crucial roles
in the lectin complement pathway [17]. In addition to
their functions in the complement system, some unex-
pected roles of these proteins have been identified in
two recent studies. Sirmaci et al. showed that homozy-
gous MASP1 mutations cause 3MC syndrome in two
unrelated families [3]. While one missense mutation
was in the exon encoding the SP domain of the protein
MASP-3, the other mutation was a nonsense variant in
the exon encoding a domain (CUB2) shared by MASP-1,
MASP-3, and MAp44 proteins [3]. Rooryck and col-
leagues described three additional missense mutations
affecting the same domain of MASP-3 protein in another
four families [2, 4, 22].
Here we report five additional MASP1 mutations.
Three missense variants found in this study affect only
the SP domain of MASP-3 and support the earlier obser-
vation that the disruption of MASP-3 with normal
MASP-1 and MAp44 is sufficient to cause 3MC syn-
drome (Fig. 1). We also present three additional patients
to the only one previously reported case with mutations
disrupting all three protein products of MASP1, MASP-1,
MASP-3 and MAp44 [3]. We previously published on
functional effects of a 3MC1 patient homozygous for a
c.870G >A (p.W290X) mutation in exon 6 of MASP1
which gave rise to no MASP-1, MASP-3 or MAp44 in
plasma of the patient. In the present report we describe
that similarly we cannot measure any MASP-1, MASP-3
or MAp44 in the plasma of patient 3, who is homozygous
for c.891 + 1G > T.
Fig. 3 Assessment of alternative and lectin pathway activity of patient 3 serum. a Rabbit erythrocyte lysis via the alternative pathway by normal
human serum (NHS) and patient 3 serum and as a negative control by NHS diluted in EDTA buffer (NHS-EDTA). The x-axis gives the dilution of
the sera tested whereas the y-axis gives the degree of lysis of the erythrocytes as measured by absorption at 405 nm of the supernatant after
incubation of sera and the cells. Representative of two experiments with similar results. Error bars for duplicates are at a size causing them to be
covered by the symbols; b C4 deposition in mannan-coated wells. Dilutions of serum from patient 3 and from a normal human serum (NHS) were
incubated in the wells. Since both sera are MBL deficient they were reconstituted with recombinant MBL to the same physiological level of 2 μg/
ml. The x-axis give the dilution of the sera and the y-axis gives the C4b deposition in counts per second as detected by anti-C4 antibodies. Repre-
sentative of two experiments with similar results. Error bars for duplicates are at a size causing them to be covered by the symbols
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It was previously reported in mice that MASP-1 was
the protease responsible for activating the proenzyme
profactor D to the active enzyme Factor D, which is es-
sential for activities of the alternative pathway of the
complement system [20]. This finding was subsequently
further extended by the same group reporting that
MASP-3 could also cleave profactor D, and in addition,
the complement factor B [21]. In a more recent paper
Ruseva and colleagues demonstrated that MASP-1 and
MASP-3 are not essential for activation of the alternative
pathway in vivo, and they noted that this occurred in the
absence of detectable mature factor D [23]. Further, it
was found that in human serum from a 3MC patient
with lack of MASP-1 and MASP-3 the proform of Factor
D was dominating [24]. Comments on the interaction of
other enzymes with profactor D giving rise to the alter-
native pathway activity that is still observed in the 3MC
patient in the absence of MASP-1 or MASP-3 as well as
an extended discussion on the assays used for the detec-
tion of activity of the alternative in the papers men-
tioned above have been published [25] and reported at
meetings [26]. Rabbit erythrocytes activate the alterna-
tive complement pathway in human serum. We thus ex-
amined the ability of serum from patient 3 to lyse rabbit
erythrocytes under conditions preventing activation of
the classical and lectin pathways. We found alternative
pathway activity being present although, as we previ-
ously reported [17], the activity does seem to be lower
than the normal human serum we tested in parallel
(Fig. 3a). Together, these results demonstrate that nei-
ther MASP-1 nor MASP-3 is crucial for alternative path-
way activity in humans. With regards to the activity of
the lectin pathway of the complement system, we tested
the ability to deposit C4 fragments onto an MBL ligand
surface (mannan). We have previously described that
MBL/MASP-1 complexes activate MASP-2 in neighbor
phenotype by testing MBL/MASP-2 complexes and that
MASP-2 then starts to cleave C4, and others have also
reported the need for MASP-1 to generate a fast and ef-
ficient lectin pathway activity [27, 28]. In accordance
with these reports, we find that serum from patient 3
had very low lectin pathway activity when compared to a
normal serum with same concentration of MBL (Fig. 3b).
It would be possible to screen for a similar biochemical
phenotype by initially testing for MASP-1 and MASP-3
levels. Testing for MASP-3 levels only may be sufficient
as we have so far only detected MASP-3 deficiency in
3MC patients despite having tested numerous patient
samples, i.e. more than 2500, representing many differ-
ent diseases. To identify the patients who do have
MASP-3 protein but a non-functional version of the
serine protease domain (e.g. harboring some of the vari-
ants in the serine protease domain as given in Fig. 1) a
substrate for MASP-3 is needed. Taking into account the
reports discussed above this could possibly be profactor
D, but more studies are needed before such tests can be
developed as also other enzymes can cleave profactor D
and a combination of catching MASP-3 in, e.g. microti-
ter wells combined with test for cleavage of profactor
may be needed for this.
The 3MC1 syndrome is a rare disorder that affects
many different tissues and organs (Table 1). Evaluation
of phenotypic findings does not show any clear-cut dif-
ference between patients who have mutations affecting
only MASP-3 and those who have mutations affecting
all three MASP1 protein products.
Although only one patient with MASP1 mutation in
the literature was reported to have anterior chamber
anomalies [3, 4], Peter’s anomaly in one patient and bi-
lateral leukoma in another patient was detected in our
study. Previously, Guion-Almeida et al. reported a clinic-
ally diagnosed 3MC case with bilateral leukoma [29].
Molecular analysis was not performed in that patient.
The presence of Peter’s anomaly and bilateral leukoma
suggests that anterior chamber abnormalities are a
genuine presentation of 3MC1 syndrome with MASP1
mutations. A number of eye abnormalities, such as
blepharophimosis, ptosis, lower eyelid eversion, anterior
chamber abnormalities, have been reported in 3MC
patients [1–3, 29]. The majority of them are eyelid
developmental abnormalities (blepharophimosis, pto-
sis, lower eyelid eversion, etc.) Anterior chamber
structures, (their abnormalities have rarely been re-
ported in 3MC syndrome) include lens, iris, ciliary
body and pupil. Certain anterior chamber anomalies
such as leukoma and cataracts, are severe and re-
quired various surgical procedures. There has been no
study investigating the effects of MASP proteins in
eye development.
Other clinical features not reported in this syndrome
until this study include a vascular anomaly and a solid
lesion in liver, absent olfactory bulbs, small pituitary,
neonatal tooth, and severe narrowing of foramen mag-
num. These additional features might be coincidental
and need further studies for conclusion. In this study,
MRI studies revealed cranial and spinal morphological
abnormalities in patients 1 and 5 and a neurosurgical
operation was performed on patient 5 for symptomatic
spinal abnormality. We thus recommend imaging studies
for detecting cranial and spinal anomalies in patients
with 3MC1 syndrome.
3MC syndrome includes overlapping features of four
syndromes, which were considered to be separate en-
tities previously. Regarding the previous nosology, when
we evaluate the patients presented here, Michels or Mal-
puech syndrome would be the most probable diagnosis
for patients 1, 4 and 5, Carnavale syndrome for patient
2, Michels or Carnavale syndrome for patient 3.
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Up to date, there have been 26 3MC patients reported,
including our 6 patients, whose causative mutations are
identified. Sixteen of them had mutations in MASP1, 10
patients had mutations in COLEC11. While comparison
of phenotypic features of patients with COLEC11 and
MASP1 mutations would be speculative because of the
limited number of patients, craniosynostosis and intel-
lectual disability were reported in 27.2 and 28.5 % of pa-
tients with MASP1 mutations, respectively, while they
were observed in 60 and 70 % of patients with COLEC11
mutations, respectively. Conversely, hearing loss, cleft
lip/palate, genital anomalies, vesicorenal anomalies, and
caudal appendages were reported to be more common
in patients with MASP1 mutations, compared to those
with COLEC11 mutations [3, 4, 22].
Conclusion
Novel MASP1 mutations and phenotypic features expand
the genotypic and phenotypic spectrum of 3MC1 syn-
drome. Patients with disrupted MASP-1 and MASP-3
have altered complement system, while their phenotype
doesn’t appear to be different from those with only dis-
rupted MASP-3. We confirm that an alternative pathway
activity is present in the MASP-1, MASP-3 and MAp44
deficient serum from a patient and that lectin pathway
activity in serum from this patient is lacking.
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